Eli Lilly (LLY -0.4%) is halting the Phase III trial of its tabalumab drug in patients with...


Eli Lilly (LLY -0.4%) is halting the Phase III trial of its tabalumab drug in patients with rheumatoid arthritis, due to insufficient efficacy. However, Lilly will continue two other Phase III studies, which are testing tabalumab for systemic lupus erythematosus, an autoimmune disease. Tabalumab's failure adds to that for AsraZeneca's fostamatinib, and follows a blow for Lilly's solanezumab treatment for Alzheimer's. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs